Join

Compare · BDX vs NEPH

BDX vs NEPH

Side-by-side comparison of Becton Dickinson and Company (BDX) and Nephros Inc. (NEPH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BDX and NEPH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BDX is the larger of the two at $41.33B, about 1122.9x NEPH ($36.8M).
  • Over the past year, BDX is down 13.0% and NEPH is down 0.9% - NEPH leads by 12.1 points.
  • BDX has hit the wire 10 times in the past 4 weeks while NEPH has been quiet.
  • BDX has more recent analyst coverage (25 ratings vs 0 for NEPH).
PerformanceBDX-12.95%NEPH-0.87%
2025-06-09+0.00%2026-06-08
MetricBDXNEPH
Company
Becton Dickinson and Company
Nephros Inc.
Price
$150.14-0.71%
$3.42-0.29%
Market cap
$41.33B
$36.8M
1M return
-2.01%
+9.44%
1Y return
-12.95%
-0.87%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
News (4w)
10
0
Recent ratings
25
0
BDX

Becton Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

NEPH

Nephros Inc.

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Latest BDX

Latest NEPH